Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy for Diffuse Large B-Cell Lymphoma: Current Landscape and Future Directions
Dipenkumar Modi, Bindu Potugari, Joseph P. Uberti
Cancers (2021) Vol. 13, Iss. 22, pp. 5827-5827
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
Tingxun Lu, Jie Zhang, Zijun Y. Xu‐Monette, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 18
Anomaly Detection and Artificial Intelligence Identified the Pathogenic Role of Apoptosis and RELB Proto-Oncogene, NF-kB Subunit in Diffuse Large B-Cell Lymphoma
Joaquim Carreras, Rifat Hamoudi
BioMedInformatics (2024) Vol. 4, Iss. 2, pp. 1480-1505
Open Access | Times Cited: 5
Bioengineering chitosan–antibody/fluorescent quantum dot nanoconjugates for targeted immunotheranostics of non-hodgkin B-cell lymphomas
Sandhra M. Carvalho, Alexandra A.P. Mansur, Zélia Inês Portela Lobato, et al.
International Journal of Biological Macromolecules (2025) Vol. 294, pp. 139515-139515
Closed Access
Prognostic significance of CDK1 expression in diffuse large B-Cell lymphoma
Qiuni Chen, Lei Xu, Chuanyang Lu, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma
Nana Ping, Changju Qu, Mengyun Li, et al.
Annals of Translational Medicine (2022) Vol. 10, Iss. 6, pp. 298-298
Open Access | Times Cited: 21
CDK1 inhibitor RO-3306 enhances BTKi potency in diffuse large B-cell lymphoma by suppressing JAK2/STAT3 signaling
Qiuni Chen, Chuanyang Lu, Dongnan Li, et al.
International Journal of Biological Macromolecules (2025) Vol. 297, pp. 139893-139893
Closed Access
Increased TIGIT expression correlates with impaired NK cell function in diffuse large B-cell lymphoma
Hui Lü, Xiaoyan Zhao, Liqiong Liu, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Combining precision oncology and immunotherapy by targeting the MALT1 protease
Thorsten R. Mempel, Daniel Krappmann
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 10, pp. e005442-e005442
Open Access | Times Cited: 17
Tumor microenvironment contribution to checkpoint blockade therapy. Lessons learned from Hodgkin lymphoma
Antonino Carbone, Annunziata Gloghini, Carmelo Carlo‐Stella
Blood (2023)
Open Access | Times Cited: 10
Unraveling the Immune Microenvironment in Diffuse Large B-Cell Lymphoma: Prognostic and Potential Therapeutic Implications
Epameinondas Koumpis, Alexandra Papoudou‐Bai, Konstantina Papathanasiou, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 7048-7064
Open Access | Times Cited: 3
Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies
Dong Zhao, Dantong Zhu, Fei Cai, et al.
Technology in Cancer Research & Treatment (2023) Vol. 22
Open Access | Times Cited: 7
Current and emerging immunotherapeutic approaches for biliary tract cancers
Zhen-gang Yuan, Tianmei Zeng, Chen‐jie Tao
Hepatobiliary & pancreatic diseases international (2022) Vol. 21, Iss. 5, pp. 440-449
Closed Access | Times Cited: 11
Novel Drugs and Radiotherapy in Relapsed Lymphomas: Abscopal Response and Beyond
Salvatore Perrone, Paolo Lopedote, Vitaliana De Sanctis, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2751-2751
Open Access | Times Cited: 6
Anti-CD19 chimeric antigen receptor T cells secreting anti-PD-L1 single-chain variable fragment attenuate PD-L1 mediated T cell inhibition
Pornpimon Yuti, Yupanun Wutti‐in, Nunghathai Sawasdee, et al.
International Immunopharmacology (2022) Vol. 113, pp. 109442-109442
Open Access | Times Cited: 10
Characterization of LIMA1 and its emerging roles and potential therapeutic prospects in cancers
Xiaoxiao Wang, Chao Zhang, Huangqin Song, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B‐cell lymphoma
Hyunjee Lee, Sang Eun Yoon, Seok Jin Kim, et al.
Cancer Medicine (2023) Vol. 12, Iss. 15, pp. 16359-16369
Open Access | Times Cited: 5
CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies
Katsiaryna Marhelava, Marta Krawczyk, Małgorzata Firczuk, et al.
Cells (2022) Vol. 11, Iss. 11, pp. 1804-1804
Open Access | Times Cited: 8
Development and validation of a combined cuproptosis and immunogenic cell death prognostic model for diffuse large B-cell lymphoma
Nana Wang, Shanshan Shi, Moran Li, et al.
Aging (2024)
Open Access | Times Cited: 1
Combination therapy of targeting CD20 antibody and immune checkpoint inhibitor may be a breakthrough in the treatment of B-cell lymphoma
Xin Wu, Sun Xiaoying, Woding Deng, et al.
Heliyon (2024) Vol. 10, Iss. 14, pp. e34068-e34068
Open Access | Times Cited: 1
Modulating JAK2/STAT3 signaling by quercetin in Qiling Baitouweng Tang: a potential therapeutic approach for diffuse large B-cell lymphoma
Xin-Zhuo Zhan, Tian‐Hua Wei, Chen Huang, et al.
Molecular Diversity (2024)
Closed Access | Times Cited: 1
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review
Romana Masnikosa, Zorica Cvetković, David Pirić
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 21, pp. 11384-11384
Open Access | Times Cited: 1
Plant Virus Intratumoral Immunotherapy with CPMV and PVX Elicits Durable Antitumor Immunity in a Mouse Model of Diffuse Large B-Cell Lymphoma
Jessica Fernanda Affonso de Oliveira, Miguel A. Moreno‐Gonzalez, Yifeng Ma, et al.
Molecular Pharmaceutics (2024)
Closed Access | Times Cited: 1
The forgotten survivor: A comprehensive review on Non‐Hodgkin lymphoma survivorship
Mohamad S. Alabdaljabar, Urshila Durani, Carrie A. Thompson, et al.
American Journal of Hematology (2022) Vol. 97, Iss. 12, pp. 1627-1637
Closed Access | Times Cited: 6
Anti‐PD‐1 therapy can possibly reverse CAR T cells exhaustion in DLBCL
Sylvain Lamure, Charles Herbaux
British Journal of Haematology (2023) Vol. 202, Iss. 2, pp. 217-218
Open Access | Times Cited: 3
Influence of Statins on the Survival Outcomes of Patients with Diffuse Large B Cell Lymphoma: A Systematic Review and Meta-Analysis
Yanbing Li, Huijie Zhou, Liqun Zou
International Journal of Clinical Practice (2022) Vol. 2022, pp. 1-9
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top